Retraction note to: Mol Cancer 19, 85 (2020)
https://doi.org/10.1186/s12943-020-01206-5
The Editor-in-Chief has retracted this article. After publication, the authors alerted the journal that there were errors in Figs. 3b, 4j, S2g and S2h, resulting in overlap between images representing different treatment groups. The Editor-in-Chief therefore no longer has confidence in the presented data.
Yiran Liang, Xiaojin Song, Yaming Li, Bing Chen, Wenjing Zhao, Lijuan Wang, Hanwen Zhang, Ying Liu, Dianwen Han, Ning Zhang, Yajie Wang, Fangzhou Ye, Dan Luo, Xiaoyan Li and Qifeng Yang agree to this retraction. Tingting Ma has not responded to any correspondence from the editor or publisher about this retraction.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liang, Y., Song, X., Li, Y. et al. Retraction Note to: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer 21, 131 (2022). https://doi.org/10.1186/s12943-022-01576-y
Published:
DOI: https://doi.org/10.1186/s12943-022-01576-y